<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03490916</url>
  </required_header>
  <id_info>
    <org_study_id>H00014860</org_study_id>
    <nct_id>NCT03490916</nct_id>
  </id_info>
  <brief_title>Effect of Acetazolamide on Subclinical High-Altitude Pulmonary Edema Detected by Lung Ultrasonography</brief_title>
  <official_title>A Prospective, Double-blind, Randomized, Placebo-controlled Trial of Acetazolamide on Subclinical High-Altitude Pulmonary Edema Detected by Lung Ultrasonography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vincent Kan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Massachusetts, Worcester</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal of this study is to detect preclinical signs of HAPE by lung ultrasonography
      and evaluate the effectiveness of acetazolamide at decreasing pulmonary edema by using
      ultrasound.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    PI was unable to continue to gather data during the trip during to medical illness
  </why_stopped>
  <start_date type="Actual">March 23, 2018</start_date>
  <completion_date type="Actual">April 4, 2018</completion_date>
  <primary_completion_date type="Actual">April 4, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pulmonary Edema Before and After Taking Acetazolamide</measure>
    <time_frame>1 month</time_frame>
    <description>Edema measured through ultrasound exam</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Completion of Ultrasound Exams</measure>
    <time_frame>1 month</time_frame>
    <description>Time it takes to complete ultrasound exams</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>High Altitude Pulmonary Edema</condition>
  <arm_group>
    <arm_group_label>Acetazolamide normal dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One (1) dose of 250mg of Acetazolamide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One (1) dose of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetazolamide</intervention_name>
    <description>Administration of Acetazolamide</description>
    <arm_group_label>Acetazolamide normal dose</arm_group_label>
    <other_name>diamox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administration of Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. At least 18 years of age

          2. Able to consent

          3. English speaking

          4. Trekking directly to Everest Base Camp

        Exclusion Criteria:

          1. Age less than 18 years

          2. Non-English speaking

          3. Pregnant

          4. Already had a diagnosis of acute mountain sickness, high-altitude cerebral edema, or
             high-altitude pulmonary edema

          5. Been on a high-altitude trek 2 weeks prior to this study

          6. Has taken acetazolamide 1 week prior to start of trek

          7. Has a sulfa allergy

          8. Has any type of acute or chronic pulmonary conditions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hillary Irons, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Massachusetts, Worcester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UMass Medical School</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>March 30, 2018</study_first_submitted>
  <study_first_submitted_qc>March 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2018</study_first_posted>
  <results_first_submitted>April 18, 2019</results_first_submitted>
  <results_first_submitted_qc>April 18, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 10, 2019</results_first_posted>
  <last_update_submitted>April 18, 2019</last_update_submitted>
  <last_update_submitted_qc>April 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Massachusetts, Worcester</investigator_affiliation>
    <investigator_full_name>Vincent Kan</investigator_full_name>
    <investigator_title>Former Fellow, Department of Emergency Medicine</investigator_title>
  </responsible_party>
  <keyword>Acetazolamide</keyword>
  <keyword>High-altitude illness</keyword>
  <keyword>High-altitude pulmonary edema</keyword>
  <keyword>Lung comets</keyword>
  <keyword>Lung ultrasound</keyword>
  <keyword>Subclinical high-altitude pulmonary edema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Altitude Sickness</mesh_term>
    <mesh_term>Pulmonary Edema</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetazolamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No ipd to share.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 14, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/16/NCT03490916/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Acetazolamide Normal Dose</title>
          <description>One (1) dose of 250mg of Acetazolamide
Acetazolamide: Administration of Acetazolamide</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>One (1) dose of placebo
Placebo: Administration of Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants were enrolled, but no participants were randomized to intervention and no participants received intervention.</population>
      <group_list>
        <group group_id="B1">
          <title>Acetazolamide Normal Dose</title>
          <description>One (1) dose of 250mg of Acetazolamide
Acetazolamide: Administration of Acetazolamide</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>One (1) dose of placebo
Placebo: Administration of Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                </category>
                <category>
                  <title>Male</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                </category>
                <category>
                  <title>Asian</title>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                </category>
                <category>
                  <title>Black or African American</title>
                </category>
                <category>
                  <title>White</title>
                </category>
                <category>
                  <title>More than one race</title>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <class_list>
            <class>
              <title>United States</title>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pulmonary Edema Before and After Taking Acetazolamide</title>
        <description>Edema measured through ultrasound exam</description>
        <time_frame>1 month</time_frame>
        <population>No participants were randomized and no participants received intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>Acetazolamide Normal Dose</title>
            <description>One (1) dose of 250mg of Acetazolamide
Acetazolamide: Administration of Acetazolamide</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One (1) dose of placebo
Placebo: Administration of Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Pulmonary Edema Before and After Taking Acetazolamide</title>
          <description>Edema measured through ultrasound exam</description>
          <population>No participants were randomized and no participants received intervention.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Completion of Ultrasound Exams</title>
        <description>Time it takes to complete ultrasound exams</description>
        <time_frame>1 month</time_frame>
        <population>Participants enrolled but not randomized and did not receive study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Acetazolamide Normal Dose</title>
            <description>One (1) dose of 250mg of Acetazolamide
Acetazolamide: Administration of Acetazolamide</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One (1) dose of placebo
Placebo: Administration of Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Completion of Ultrasound Exams</title>
          <description>Time it takes to complete ultrasound exams</description>
          <population>Participants enrolled but not randomized and did not receive study drug.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Due to investigator illness, no participants were randomized and no study drug was administered.</time_frame>
      <desc>Due to investigator illness, no participants were randomized and no study drug was administered.</desc>
      <group_list>
        <group group_id="E1">
          <title>Acetazolamide Normal Dose</title>
          <description>One (1) dose of 250mg of Acetazolamide
Acetazolamide: Administration of Acetazolamide</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>One (1) dose of placebo
Placebo: Administration of Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to Investigator illness, although participants were enrolled, no participants were randomized to receive interventions and did not receive study drug.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Principal Investigator</name_or_title>
      <organization>UMass Medical School</organization>
      <phone>4136279111</phone>
      <email>vincent.kan08@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

